STITCHERADS
21.5.2014 09:06:24 CEST | Business Wire | Pressemeddelelse
SticherAds, the social performance advertising platform for online retailers, today revealed it is one of a select few companies to complete the pilot Preferred Marketing Developer (PMD) Ads Incubator Program at Facebook® headquarters in Menlo Park, California.
Recently qualified as a PMD for Ads by Facebook, StitcherAds today also announces the launch of the newest edition of its Software as a Service (SaaS) platform, enabling online retailers to quickly put an ad for the right product in front of the right consumer at the right time and on the right device.
A brand new method of retargeting prospective buyers, StitcherAds’ new offering is a comprehensive yet affordable advertising suite allowing retailers to create more consistent and measurable returns on their Facebook advertising investments. In a major innovation for the industry, StitcherAds charges on a monthly subscription basis rather than percentage of ad spend model.
StitcherAds, previously known as Betapond, has consistently led in marketing innovation on the Facebook platform. Selected for ‘incubation’ by Facebook at its HQ, following a competitive selection process, the StitcherAds development team there refined its revolutionary method of analysing site behavioural data helping place the most attractive offers in front of the correct consumers. This allows retailers unparalleled prospecting and retargeting across desktop, tablet, and mobile.
Michael Randall, global director of Facebook’s preferred marketing developer program, said: “ StitcherAds' focus on online retailers is a great example of how our PMD partner ecosystem is becoming more diverse, to better support the vertical-specific needs of advertisers. StitcherAds' engineering culture has a lot in common with Facebook's own and we were delighted to work with them."
StitcherAds helps online retail marketers in three ways:-
Saves precious time
Facebook isn’t just about scale, despite having 1.2 Billion people. It also now enables powerful targeted reach for Direct Response advertisers. But it can be time consuming to use native tools like PowerEditor or other solutions not specifically designed for the needs of online retailers. Because StitcherAds is designed around the needs of online retail marketers – making it easy to create ads at scale from the feed of a product catalogue, for example – its features enable significant time savings. Allowing for more ad testing, more inventory changes and better sales.
More comprehensive retargeting
StitcherAds sees 70% of impressions and 65% of conversions now happening for its customers on tablet and mobile. But many retailers continue to use remarketing solutions that only reach people on desktop. StitcherAds makes it easy to prospect and retarget people with the right product across device and measure their response in near real time. Unlike other remarketing solutions, StitcherAds stops showing ads to consumers who have already bought the product, preventing wastage and potential brand damage.
Sophisticated Rules-based Optimisation
StitcherAds lets retailers create rules to automatically turn off ads falling below key performance criteria such as Cost Per Acquisition, or for products with limited stock. Equally, StitcherAds rewards the most effective ads providing insights for sharper retailer advertising – protecting their budget even while the marketer is sleeping.
A key benefit of this enhanced advertising armoury is that retailers such as outdoor flash sales specialist SportPursuit, can match the right buyer at the right time in their decision-making process to optimize the return on their social ad spend.
Anna Gardner, online marketing manager for SportPursuit, said: “ StitcherAds has reduced by more than 50% the amount of time it takes us to get campaigns live. This has allowed us to experiment further with campaigns targeting, the content of our ads and focus on strategy rather than manual workload."
Declan Kennedy, CEO and Co-Founder of StitcherAds said, “The savviest online retailers now realise that Facebook is a key channel for driving customer acquisition and incremental sales growth. Some of the very best now see Facebook as their most important DR channel with investments to back it up and StitcherAds, bringing to market the technology we refined onsite at Facebook’s campus, is making it easier for online retailers to grasp that opportunity before their competitors do.”
Facebook® is a registered trademark of Facebook Inc.
About StitcherAds
StitcherAds is the SaaS social performance ads platform specifically designed for online retailers to help them manage and optimize direct response ads on Facebook. The platform stitches together the retailer’s 1st party data with Facebook’s targeted reach at scale, enabling them to win 33% more customers in 67% less time.
StitcherAds is a Preferred Marketing Developer for Ads and has worked with savvy retailers including Lyle & Scott, SportPursuit, Tiffany Rose and Pets Pyjamas. Founded in 2009 as Betapond, the company’s investors include Investec Ventures Ireland, Delta Partners, Irrus Investments and Enterprise Ireland.
For more information
Contact:
Positive Marketing (for StitcherAds)
Paul Maher or Benedict
Sycamore, +44 20 3637 0640
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum